Fonagepant
Fonagepant (FE 205030) is a calcitonin gene-related peptide (CGRP) receptor antagonist with an IC50 of 0.2 nM. Fonagepant selectively blocks CGRP receptor activity, inhibits CGRP-induced vasodilation, attenuates capsaicin-induced increase in skin blood flow, and blocks CGRP-induced vasodilation in isolated human mesenteric resistance arteries. Fonagepant can be used in studies related to acute migraine attacks.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 1966181-14-5
- 分子式: C66H88N16O16S2
- 分子量:1425.63
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
0.2 nM
|
Inhibition of human CGRP receptor-mediated cAMP production in stably transfected HEK cells measured via time-resolved fluorescence resonance energy transfer.
Inhibition of human CGRP receptor-mediated cAMP production in stably transfected HEK cells measured via time-resolved fluorescence resonance energy transfer.
|
34217775 |
体外実験
Fonagepant (0.3-10 nM) potently blocks αCGRP-induced vasodilation of isolated human mesenteric resistance arteries, with a mean pA2 value of 9.3, and acts as a competitive antagonist[1].
Fonagepant potently inhibits cAMP production mediated by the human CGRP receptor, with an IC50 of 0.2 nM, and exhibits high selectivity for human AM1R and AM2R receptors in stably transfected HEK cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Parmacokinetics
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult male (3.0-4.0 kg)[1]
-
Dosage:3 nM; 10 nM; 30 nM; 100 nM; 300 nM (target steady-state plasma concentrations)
-
Administration:i.v. bolus plus infusion
-
Result:Did not inhibit capsaicin-induced increases in skin blood flow relative to the control at 3 nM target steady-state plasma concentration.
Caused inhibition of capsaicin-induced skin blood flow increases beginning at 25 minutes post-capsaicin application at 10 nM target steady-state plasma concentration.
Caused inhibition of capsaicin-induced skin blood flow increases beginning at 20 minutes post-capsaicin application at 30 nM target steady-state plasma concentration.
Caused inhibition of capsaicin-induced skin blood flow increases beginning at 15 minutes post-capsaicin application at 100 nM target steady-state plasma concentration.
Caused inhibition of capsaicin-induced skin blood flow increases beginning at 25 minutes post-capsaicin application at 300 nM target steady-state plasma concentration.
Exhibited maximal inhibitory activity at circulating concentrations of 30-100 nM, where all treated animals showed decreased skin blood flow responses relative to controls.
Resulted in measured plasma concentrations within 1.4-fold of target values.
化学情報
-
CAS 番号 1966181-14-5
-
分子量 1425.63
-
分子式 C66H88N16O16S2
-
別名
FE 205030
-
配列
{d-Val}-{Phe(CONH2)}-Cys-{Orn(1-methylethyl)}-Asp-Val-Gly-Pro-Phe-Cys-{Val(3-pyridinyl)}-NH2 (Disulfide bridge: Cys3-Cys10)
-
シーケンスの短縮
{d-Val}-{Phe(CONH2)}-C-{Orn(1-methylethyl)}-DVGPFC-{Val(3-pyridinyl)}-NH2 (Disulfide bridge: Cys3-Cys10)
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Fonagepant 関連分類
HY-P12136 関連分類
Powered by Bioz